soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results Oral Semaglutide Reduces CV Events
Description
GLP1 Medication Bottom Line GLP-1 receptor agonists are not a trend or a celebrity weight loss shortcut
it resulted from the continuous activation of the GLP1 pathway
Dehydration is a major contributor that many patients overlook
With the right guidance, it can easily be managed
The Precision Peptide Genetic Test identifies your genetic response to GLP-1 signaling and other peptide pathways, but not optimal injection timingthat depends on your lifestyle and adherence
Statistical analysis Statistical analyses were performed by one-way ANOVA followed by Bonferronis post-test for multiple comparisons, as appropriate
